Acute Lymphoblastic Leukemia/Lymphoma, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplasia
Conditions
Brief summary
This is a prospective non-therapeutic study, assessing the long-term toxicity of pediatric HCT for hematologic malignancies. This study is a collaboration between the Pediatric Blood and Marrow Transplant Consortium (PBMTC), the Center for International Blood and Marrow Transplant Research (CIBMTR), the National Marrow Transplant Program (NMDP) and the Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI-BMT) of the CIBMTR. The study will enroll pediatric patients who undergo myeloablative HCT for hematologic malignancies at PBMTC sites.
Detailed description
This is a prospective non-therapeutic study, assessing the long-term toxicity of pediatric HCT for hematologic malignancies. This study is a collaboration between the Pediatric Blood and Marrow Transplant Consortium (PBMTC), the Center for International Blood and Marrow Transplant Research (CIBMTR), the National Marrow Transplant Program (NMDP) and the Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI-BMT) of the CIBMTR. The study will enroll pediatric patients who undergo myeloablative HCT for hematologic malignancies at PBMTC sites. The study examines the hypothesis that survivors of pediatric HCT are at risk for late organ toxicity and they will have identifiable biomarkers present within the first two years following HCT which will be predictive for late adverse outcomes allowing for early identification of patients at risk.
Interventions
None listed
Sponsors
Pediatric Blood and Marrow Transplant Consortium
National Marrow Donor Program
Center for International Blood and Marrow Transplant Research
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 22 Years
Healthy volunteers
No
Inclusion criteria
1. Age less than 22 years at admission for HCT 2. Planned allogeneic HCT from any donor and stem cell source. There are no study-specific criteria for HLA-matching 3. Disease and disease status criteria 1. Acute lymphoblastic leukemia/lymphoma in complete morphologic remission defined as a M1 marrow (\<5% blasts) with no evidence of active extramedullary disease within 30 days of the start of the conditioning regimen; OR 2. Myelodysplasia (regardless of subtype) with less than 10% marrow blasts within 30 days of the start of the conditioning regimen; OR 3. Acute myelogenous leukemia in complete morphologic remission defined as an M1 marrow (\<5% blasts) with no evidence of extramedullary disease within 30 days of the start of the conditioning regimen; OR 4. Juvenile myelomonocytic leukemia; OR 5. Chronic myelogenous leukemia excluding refractory blast crisis. 4. Planned myeloablative conditioning regimen, defined as a regimen including one of the following as a backbone agent: 1. Busulfan ≥ 12.8 mg/kg total dose (IV or PO). PK-based dosing allowed, if the intent is total overall dose ≥ 12.8 mg/kg; OR 2. Total Body Irradiation ≥ 1200 cGy fractionated; OR 3. Treosulfan ≥ 30 g/m2 total dose IV 5. Enrollment in the following NMDP research protocols: 1. Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxicity Injuries 2. Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries 6. Written informed consent document signed by patient if the age is greater than or equal to 18 years and the patient is developmentally able to provide consent. The informed consent document is to be signed by the parent or legal guardian if the patient's age is less than 18 years or if the patient is older than 18 years, but developmentally unable to provide consent. Assent will be obtained according to the guidelines of the patient's transplant institution.
Exclusion criteria
1. Prior allogeneic or autologous HCT 2. Patients with renal disease prior to the start of HCT conditioning requiring the use of dialysis at the time of enrollment and/or GFR \< 60 mL/min/1.73 m2 3. Patients with osteopenia or osteoporosis treated with a bisphosphonate medication at any time prior to enrollment 4. Patients with preexisting diabetes or hyperglycemia treated with insulin or oral hypoglycemic medication at the time of enrollment 5. Patients with uncontrolled viral, bacterial, fungal or protozoal infection at the time of study enrollment 6. Karnofsky performance score or Lansky Play-Performance Scale Score \<60 at the time of study enrollment 7. Known inherited or constitutional predisposition to cancer including, but not limited to Down Syndrome, Li-Fraumeni syndrome, Fanconi Anemia, and patients with BRCA1 and BRCA2 mutations
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To report the incidence of chronic kidney disease (CKD), metabolic syndrome, and osteopenia | Baseline to 1 and 2 years following allogeneic HCT for hematologic malignancy |
Secondary
| Measure | Time frame |
|---|---|
| To investigate potential associations of systemic hypertension as measured with intermittent blood pressure assessment with proteinuria, acute kidney injury, and CKD | Baseline to 100 days, and at 1 and 2 years following HCT |
| To compare the results of GFR estimating equations based on serum cystatin C levels or serum creatinine to GFR measured by nuclear medicine GFR and/or 24-hour creatinine clearance | Baseline to 180 days, and at 1 and 2 years following HCT |
| To explore potential association of the protein biomarker elafin in the urine at with the development of CKD | Baseline to 180 days, and at 1 and 2 years following HCT |
| To report levels of fasting triglycerides, low-density lipoprotein, high-density lipoprotein, insulin, and glucose levels | Baseline to 100 days, and at 1 and 2 years following HCT |
| To identify prognostic risk factors for the development and progression of post-HCT CKD, metabolic syndrome, and osteopenia | Baseline to 1 and 2 years following HCT |
| To assess the presence of osteopenia prior to HCT and at 1-year and 2-years following HCT by x-ray in patients unable to undergo DXA without sedation | Baseline to 1 and 2 years following HCT |
| To report levels of markers of bone turnover including serum osteocalcin, bone specific alkaline phosphatase, and urine N-telopeptide | Baseline to 30 days, 100 days, and at 1 and 2 years following HCT |
| To develop a repository for plasma to be used in future investigation of HCT-associated late effects | Baseline, 30 days, 100 days, and at 1 and 2 years following HCT |
| To assess change in body composition including bone mineral density, body mass index, percent fat mass and lean body mass as measured by dual-energy absorptiometry | Baseline to 1 and 2 years following HCT |
Countries
United States
Outcome results
None listed